K01G5.5 Antibody

What is K01G5.5 in C. elegans and what is its functional role?

K01G5.5 is a gene in Caenorhabditis elegans that encodes a protein orthologous to human Dyskerin. Based on current research, K01G5.5 is involved in core cellular processes and is particularly implicated in RNA processing mechanisms . The protein likely functions in ribosome biogenesis and telomere maintenance, similar to its human counterpart.

Methodologically, researchers investigating K01G5.5 function should consider:

• Generating tissue-specific expression models using various promoters (e.g., spp-5 for intestine expression)

• Examining phenotypes across developmental stages from embryonic to adult

• Comparing phenotypes with human Dyskerin dysfunction models to identify conserved mechanisms

• Employing both forward and reverse genetic approaches to elucidate function

K01G5.5 mutations may potentially disrupt fundamental cellular processes including translation, RNA modification, and chromosome maintenance, making it a significant target for developmental biology and disease model research.

How does K01G5.5 relate to human disease models?

K01G5.5 is the C. elegans ortholog of human Dyskerin, which when mutated leads to X-linked dyskeratosis congenita . This rare genetic disorder is characterized by bone marrow failure, skin abnormalities, and increased cancer susceptibility.

For researchers using K01G5.5 in disease modeling:

• RNA processing defects should be quantified through ribosome profiling and RNA-seq

• Telomere length should be measured in K01G5.5 mutants compared to wild-type worms

• Cell proliferation rates in germline tissue can serve as an analog to human hematopoietic effects

• Protein-protein interaction studies should focus on telomerase complex components and H/ACA snoRNP subunits

• Cross-species rescue experiments can determine functional conservation between C. elegans K01G5.5 and human DKC1

What expression systems are optimal for K01G5.5 antibody production?

While the search results don't specify commercial antibody production systems for K01G5.5, general principles for C. elegans protein antibodies apply:

For bacterial expression systems:

• Express only hydrophilic domains to avoid solubility issues

• Use tags (His, GST, MBP) that can be removed by protease cleavage before immunization

• Express in E. coli strains optimized for eukaryotic proteins (e.g., Rosetta for rare codons)

• Purify under native conditions when possible to preserve antigenic epitopes

For mammalian expression systems:

• Use HEK293 or CHO cells for post-translational modifications

• Consider tetracycline-inducible systems for toxic proteins

• Collect and concentrate secreted proteins from conditioned media

• Verify protein folding through functional assays before immunization

The expression construct concentration should be carefully titrated; for K01G5.5, similar C. elegans proteins have been successfully expressed using 10 ng/μl of construct with 90 ng/μl pBSK carrier DNA .

What detection methods are available for K01G5.5 in C. elegans tissues?

Several complementary approaches can be employed for detecting K01G5.5 expression in C. elegans:

• Fluorescent protein tagging:

  • GFP-tagged K01G5.5 can be visualized in live worms at various developmental stages

  • Animals should be immobilized with 1 mM levamisole before imaging

  • Confocal microscopy provides optimal resolution for subcellular localization

• Immunostaining protocols:

  • Fix worms using paraformaldehyde or methanol-acetone methods

  • Permeabilize with 0.5% Triton X-100 in PBS

  • Block with 1% bovine serum albumin

  • For tagged versions, use anti-tag antibodies (e.g., anti-GFP at 1:500 dilution)

  • Image using appropriate fluorescent secondary antibodies

• Enzymatic tagging approaches:

  • APX-based proximity labeling can identify neighboring proteins

  • Biotin-phenol substrate treatment followed by H₂O₂ activation enables spatially restricted labeling

  • Detect biotinylated proteins using streptavidin conjugates

These methods can be combined for comprehensive expression analysis across tissues and developmental stages.

What validation steps are essential for K01G5.5 antibodies?

Before using K01G5.5 antibodies in experiments, several validation steps are crucial:

• Western blot validation:

  • Confirm single band of expected molecular weight (~58-60 kDa)

  • Test antibody specificity using RNAi or mutant samples as negative controls

  • Compare results across different tissues and developmental stages

• Immunofluorescence validation:

  • Verify expected subcellular localization (likely nucleolar)

  • Confirm absence of signal in negative controls

  • Test multiple fixation protocols to optimize epitope accessibility

  • Compare with localization of tagged K01G5.5 protein

• Immunoprecipitation validation:

  • Confirm ability to pull down K01G5.5 from worm lysates

  • Verify interacting partners match known dyskerin-associated proteins

  • Assess background binding using pre-immune serum controls

• Cross-reactivity assessment:

  • Test against closely related proteins in C. elegans

  • Confirm specificity against human dyskerin if cross-species usage is intended

A typical validation approach would include both genetic controls (RNAi, mutants) and molecular controls (peptide competition, pre-immune serum) .

How can I optimize immunoprecipitation protocols for K01G5.5 studies?

Immunoprecipitation of K01G5.5 requires careful optimization:

• Lysate preparation:

  • Synchronize worm populations (typically at L4 stage)

  • Harvest 30,000-50,000 worms per condition

  • Flash-freeze in liquid nitrogen and grind thoroughly

  • Extract with buffer containing:

    • 50 mM HEPES (pH 7.4)

    • 150 mM NaCl

    • 1% Triton X-100

    • 0.1% SDS

    • 1 mM EDTA

    • Protease inhibitor cocktail

  • Centrifuge at 21,000 g, 4°C for 10 minutes

  • Pre-clear lysate with protein A/G beads

• Immunoprecipitation procedure:

  • Use 450-550 μg protein per immunoprecipitation

  • Incubate with antibody (5-10 μg) overnight at 4°C

  • Add protein A/G beads for 1-2 hours

  • Wash 5× with lysis buffer

  • Wash 3× with high-salt buffer (300 mM NaCl)

  • Wash 3× with PBS

• Elution strategies:

  • For denaturing conditions: SDS sample buffer at 95°C

  • For native conditions: peptide competition or low pH elution

  • For mass spectrometry: on-bead trypsin digestion (100 μl of 0.1 μg/μl trypsin)

• Controls and validation:

  • Include IgG control immunoprecipitation

  • Use K01G5.5 mutant or RNAi-treated worms as negative controls

  • Consider isotopic labeling for quantitative comparison of specific versus non-specific binding

What is the relationship between K01G5.5 and condensin complexes in C. elegans?

While direct evidence linking K01G5.5 to condensin complexes is not presented in the search results, several methodological approaches can be used to investigate potential interactions:

• Protein interaction analysis:

  • Condensin in C. elegans consists of SMC subunits (MIX-1, SMC-4) and complex-specific CAP subunits

  • Co-immunoprecipitation experiments with K01G5.5 antibodies followed by probing for condensin components could reveal physical interactions

  • Mass spectrometry of K01G5.5 immunoprecipitates should be examined for condensin subunits

  • The novel SMC-like protein SMCL-1 that interacts with condensin should be included in interaction studies

• Functional relationship assessment:

  • Genetic interaction studies between K01G5.5 and condensin components (double mutant/RNAi analysis)

  • Examination of chromosome morphology in K01G5.5 mutants compared to condensin mutants

  • Analysis of whether K01G5.5 depletion affects condensin loading onto chromatin

• Localization studies:

  • Co-immunostaining for K01G5.5 and condensin components across cell cycle stages

  • ChIP-seq analysis to identify potential co-localization on chromatin

  • Proximity labeling approaches to determine if K01G5.5 and condensin components occupy neighboring spaces

How can CRISPR-Cas9 be applied for K01G5.5 functional studies?

CRISPR-Cas9 genome editing provides powerful approaches for K01G5.5 functional studies:

• Guide RNA design considerations:

  • Target conserved domains for knockout studies

  • Use tools like CRISPOR to minimize off-target effects

  • When tagging, place guide RNA cut sites near the desired insertion location

  • For precise modifications, include PAM site mutations in repair templates

• Recommended editing strategies:

  • N-terminal tagging: Insert fluorescent proteins while preserving nucleolar localization signals

  • C-terminal tagging: Add small epitope tags (FLAG, HA) that minimize functional disruption

  • Domain-specific mutations: Target catalytic residues to create separation-of-function alleles

  • Conditional alleles: Insert LoxP sites for tissue-specific deletion using Cre recombinase

• Delivery and screening protocol:

  • Microinject young adult hermaphrodite gonads with:

    • Cas9 expression plasmid (50 ng/μl)

    • sgRNA expression vectors (25 ng/μl each)

    • Repair template (50 ng/μl)

    • Co-injection markers (myo-2p::mCherry at 10 ng/μl)

  • Screen F1 progeny for fluorescent markers

  • Isolate F2 homozygotes

  • Confirm edits by PCR and sequencing

• Validation of edited lines:

  • Phenotypic analysis across development

  • RNA and protein expression verification

  • Functional rescue experiments

  • Comparison with RNAi phenotypes

The MosSCI method mentioned for generating single-copy transgenes provides an alternative approach if CRISPR editing proves challenging.

What are the most effective strategies for studying K01G5.5 protein interactions in vivo?

Several complementary approaches can be employed to study K01G5.5 protein interactions in live C. elegans:

• Proximity-based labeling:

  • Express K01G5.5 fused to enzymes like APX, BioID or TurboID

  • Treat animals with biotin-phenol substrate for 1 hour followed by H₂O₂

  • Isolate biotinylated proteins using streptavidin agarose resin

  • Wash extensively and digest on-bead with trypsin

  • Identify labeled proteins by mass spectrometry

• Quantitative immunoprecipitation:

  • Use stable isotope labeling methods to compare specific versus non-specific interactions

  • Options include stable isotope dimethyl labeling using CH₂O/CD₂O/C¹³D₂O with appropriate reducing agents

  • Combine differentially labeled samples for mass spectrometry analysis

  • Set significance thresholds based on enrichment ratios

• Tissue-specific interaction mapping:

  • Express tagged K01G5.5 under tissue-specific promoters

  • Options include intestine-specific (spp-5), epidermis-specific (dpy-7), muscle-specific (myo-3)

  • Compare interaction networks across tissues

  • Focus on interactions conserved across multiple tissues versus tissue-specific interactions

How does K01G5.5 expression change throughout C. elegans development?

To comprehensively characterize K01G5.5 expression across developmental stages:

• Transcriptional profiling:

  • Collect synchronized populations at key developmental stages

  • Extract RNA and perform RT-qPCR using K01G5.5-specific primers

  • Normalize to stable reference genes like rps-23

  • Compare with existing RNA-seq developmental time course data

• Protein-level analysis:

  • Prepare lysates from synchronized worm populations

  • Perform Western blotting with K01G5.5 antibodies

  • Quantify using appropriate loading controls

  • Consider quantitative proteomics approaches with isotopic labeling

• Spatiotemporal expression patterns:

  • Generate transgenic worms expressing K01G5.5::GFP

  • Image animals at different developmental stages

  • Document expression patterns across tissues

  • Use confocal microscopy for subcellular localization

Based on patterns observed with other nuclear proteins in C. elegans, expression likely remains consistent throughout development but may show tissue-specific regulation .

What controls are essential when performing Western blots with K01G5.5 antibodies?

When conducting Western blot analysis with K01G5.5 antibodies, several critical controls must be included:

• Genetic controls:

  • Wild-type extract as positive control

  • K01G5.5 RNAi or mutant extract as negative control

  • Extract from worms overexpressing K01G5.5 to confirm band identity

  • The Western blot example in search result demonstrates how a mutation renders the target protein undetectable, validating antibody specificity

• Technical controls:

  • Molecular weight markers to confirm expected size (~58-60 kDa for K01G5.5)

  • Loading controls such as actin or tubulin antibodies on stripped membranes

  • Concentration series to ensure signal linearity

  • Secondary antibody-only control to detect non-specific binding

• Antibody validation controls:

  • Pre-incubation with immunizing peptide/protein to confirm specificity

  • Testing multiple antibody dilutions (typically 1:500 to 1:5000)

  • Comparison of results from antibodies targeting different epitopes

  • Cross-reactivity assessment with related C. elegans proteins

• Sample preparation controls:

  • Fresh vs. frozen sample comparison

  • Different lysis buffer compositions to optimize extraction

  • Phosphatase/protease inhibitor inclusion vs. exclusion

  • Heat vs. non-heat denatured samples to detect potential aggregation

A recommended control panel might include wild-type, RNAi-treated, overexpression, and mutant samples run in parallel, with both K01G5.5 and control antibody (e.g., actin) detection .

What are the technical challenges in generating specific antibodies against K01G5.5?

Generating specific antibodies against K01G5.5 presents several technical challenges:

• Epitope selection considerations:

  • Avoid highly conserved domains that could lead to cross-reactivity

  • Target C. elegans-specific regions not present in other orthologs

  • Select regions predicted to be surface-exposed in the native protein

  • Consider multiple peptides targeting different regions

• Expression system optimization:

  • Test both bacterial and eukaryotic expression systems

  • For bacterial systems, use specialized strains for rare codons

  • Express protein fragments rather than full-length protein if solubility issues arise

  • Purify under native conditions when possible to preserve epitope structure

• Purification strategy refinement:

  • Use affinity tags that can be removed before immunization

  • Implement multiple purification steps to ensure high purity

  • Verify protein identity by mass spectrometry before immunization

  • Test multiple buffer conditions to maintain protein stability

• Immunization protocol customization:

  • Compare multiple adjuvants for optimal immune response

  • Use extended immunization schedules for poorly immunogenic proteins

  • Test sera throughout the immunization process to track antibody development

  • Consider using multiple host species for greater epitope coverage

• Validation requirements:

  • Test antibody against recombinant protein and worm lysates

  • Verify absence of signal in K01G5.5 mutants or RNAi-treated worms

  • Assess tissue localization pattern matches expected expression

  • Confirm reproducibility across multiple antibody production batches

Integrating findings across model systems

K01G5.5 research in C. elegans provides valuable insights that can be translated to human dyskerin studies. The data from various experimental approaches should be integrated to build a comprehensive understanding of K01G5.5 function. Researchers should consider:

• Comparing phenotypes between C. elegans K01G5.5 mutants and human dyskerin mutations

• Establishing whether K01G5.5 interacts with condensin components like those described in search results

• Utilizing advanced proximity labeling techniques to map the protein's interaction network in vivo

• Developing tissue-specific and conditional alleles to dissect functions in different contexts

The research tools and methodologies outlined in this FAQ collection provide a foundation for advancing our understanding of this important protein, potentially contributing to insights into dyskeratosis congenita and related disorders.

Methodological recommendations and best practices

Based on the available research and technical considerations, investigators working with K01G5.5 antibodies should:

• Thoroughly validate all antibodies using multiple approaches before experimental application

• Include appropriate controls in all experiments, particularly genetic controls

• Consider protein tagging approaches when antibodies prove challenging to develop

• Employ multiple complementary techniques to confirm findings

• Share validated reagents and protocols with the research community to accelerate progress